Nandrolone Other names: Decanoate nandrolone 19-nortestosterone

In patients with pre-existing cardiac, renal or hepatic insufficiency/disease or epilepsy or migraine anabolic steroid treatment may cause complications characterized by oedema with or without congestive heart failure. In such cases treatment must be stopped immediately. Patients who experienced myocardial infarction, cardiac-, hepatic- or renal insufficiency, hypertension, epilepsy, or migraine should be monitored due to the risk of deterioration of or reoccurrence of disease. In such cases treatment must be stopped immediately.

Caution should be used in patients with severe hepatic impairment and nandrolone should only be used if the benefits outweigh the risks.

Anabolic steroids may improve glucose tolerance and decrease the need for insulin or other anti-diabetic drugs in diabetic patients. Patients with diabetes mellitus should therefore be monitored especially at the beginning or end of treatment and at periodic intervals during nandrolone treatment.

High doses of nandrolone may enhance the anti-coagulant action of coumarin- type agents. Therefore close monitoring of prothrombin time and if necessary a dose reduction of the anti-coagulant is required during therapy.

The concurrent administration of anabolic steroids with ACTH or corticosteroids may enhance edema formations; thus these active substances should be administered cautiously, particularly in patients with cardiac or hepatic disease or in patient predisposed to edema.

In men treatment with nandrolone can lead to fertility disorders by repressing sperm-formation. In women treatment with androgens can lead to an infrequent or repressed menstrual cycle.

Combination of nandrolone with rhEPO (recombinant human erythropoietin), especially in females, may enable a reduction of the erythropoietin dose to reduce anemia.

Anabolic steroids may decrease levels of thyroxine-binding globulin resulting in decreased total T4 serum levels and increases resin uptake of T3 and T4. Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.

Patients should be informed about the potential occurrence of signs of virilisation. In particular, singers and women with speech professions should be informed about the risk of deepening of the voice. If signs of virilisation develop, the risk/benefit ratio has to be newly assessed with the individual patient.

Mammary carcinoma, hypernephroma, bronchial carcinoma and skeletal metastases. In these patients hypercalcaemia or hypercalciuria may develop spontaneously, and also during androgen therapy. Nevertheless, the hypercalcaemia or hypercalciuria should first be treated appropriately and after restoration of normal calcium levels, if judged necessary and taking into account the risks and benefits on a case by case basis, hormone therapy can be resumed, with caution.

Nandrolone is contra-indicated in women who are pregnant.

There are no adequate data for the use of nandrolone in pregnant women. In view of the risk of virilisation of the foetus, nandrolone should not be used during pregnancy. Treatment with nandrolone should be discontinued when pregnancy occurs.

There are no adequate data for the use of this medicine during lactation to assess potential harm to the infant or a possible influence on milk production. Therefore, nandrolone should not be used during lactation.

Fertility

In men treatment with nandrolone can lead to fertility disorders by repressing sperm-formation. In women treatment with androgens can lead to an infrequent or repressed menstrual cycle.

Nandrolone has no influence on the ability to drive and use machines.